Phase 2 Brain Cancer Trial, Recruiting NCT05708352 Sponsor: Cedars-Sinai Medical Center Condition: Brain Cancer
Back to Brain Cancer

Phase 2 Brain Cancer Trial, Recruiting

NCT05708352
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 years or older
  • People who have been recently diagnosed with glioblastoma (a type of brain tumour), with the diagnosis confirmed by a tissue test within the last 2 months
  • People who have not yet started standard chemotherapy or radiation treatment for glioblastoma
  • People whose physical functioning meets a minimum level on a medical scale called the Karnofsky Performance Status, scored at 70 or above (confirm with trial site)
  • People who are able to read, write, and understand English or Spanish
  • People who are willing and able to provide written consent to participate and to follow the study requirements

Who may not be able to join:

  • People whose glioblastoma has come back after previous treatment
  • People with inherited conditions that affect how the body processes fats, such as pyruvate carboxylase deficiency, porphyria, primary carnitine deficiency, or certain other related genetic disorders
  • People who cannot reduce their steroid medication below a certain daily dose (8mg of dexamethasone per day, or an equivalent amount)
  • People with a Body Mass Index (a measure of body weight relative to height) below 21, unless the trial site's lead doctor considers it safe
  • People who are currently pregnant or breastfeeding
  • People who are already taking part in another experimental treatment study (note: use of medicines outside their approved purpose is allowed)
  • People with other health conditions that, in the opinion of the trial doctor, would prevent them from completing the study
  • People whose food preferences are not compatible with a ketogenic (very low carbohydrate, high fat) diet
  • People who use certain electronic medical devices, such as a pacemaker, implantable heart defibrillator, neurostimulator, or cochlear implants — unless the trial site's lead doctor considers participation safe (removable hearing aids are permitted)
  • People who are unable to have standard MRI scans as part of their care

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jethro Hu, MD, Cedars-Sinai Medical Center

Phone: 3104232133

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Cedars-Sinai Medical Center
Registry
ClinicalTrials.gov
Start date
27 June 2023
Est. completion
30 September 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov